Poxel's Financial Overview: Q3 2024 Highlights and Future Outlook
Poxel SA, a clinical-stage biopharmaceutical company, recently released its revenue and cash position for the third quarter of 2024. With a focus on innovative treatments for serious chronic diseases with metabolic pathophysiology, Poxel is making significant strides, particularly in the management of metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes.
Corporate Updates
As of September 30, 2024, Poxel reported revenues of EUR 854 thousand for the third quarter. This figure contributes to a total of EUR 2,016 thousand over the nine months of the year, reflecting a notable increase compared to EUR 1,619 thousand during the same period in 2023. This positive revenue trajectory is largely attributed to the sales performance of TWYMEEG® (Imeglimin) in Japan, which saw gross sales rise significantly.
TWYMEEG® Performance
Poxel is thrilled with the ongoing sales trajectory of TWYMEEG® in Japan, estimating net sales to potentially reach JPY 5 billion in the upcoming months. This milestone entitles Poxel to 10% royalties on all TWYMEEG® net sales and a sales-based payment of JPY 500 million (EUR 3.1 million). These financial benefits will aid in executing repayment strategies for existing bonds related to the agreement with OrbiMed.
Cash Position Strengthened
The company's total cash and cash equivalents reached EUR 13.1 million (USD 14.7 million) as of the end of September 2024. This amount significantly surpasses the EUR 2.8 million reported at the end of June 2024, showcasing a robust improvement in Poxel's liquidity position, enabling continued investment in its development pipeline.
Revenue Insights
Poxel's revenue primarily arises from the successful Royalties from the Sumitomo Pharma agreement, which underpin the overall financial performance. Royalty revenues of JPY 328 million (EUR 2,016 thousand) from TWYMEEG® illustrate the product’s growing market acceptance and performance.
Future Financial Expectations
Looking ahead, Poxel anticipates that its cash resources will be adequate to cover operations and capital expenditures until the end of 2025, driven by planned strategic initiatives and a focus on controlling operating expenses efficiently. Poxel remains optimistic about ongoing discussions with regulatory authorities in Japan to optimize the TWYMEEG® package insert.
About Poxel SA
Poxel is dedicated to developing innovative solutions for chronic illnesses, primarily through products like TWYMEEG®, which has gained traction in Japan as a treatment for type 2 diabetes. The company also actively engages in the development of PXL065 for MASH and PXL770 for rare diseases, showcasing its commitment to addressing serious health conditions.
Upcoming Financial Releases
- First Half Results on December 9, 2024
- Fourth Quarter 2024 Cash and Revenue update on February 12, 2025
Frequently Asked Questions
What were Poxel's revenues for Q3 2024?
Poxel reported revenues of EUR 854 thousand for the third quarter of 2024.
How much cash does Poxel have as of September 30, 2024?
Poxel had total cash and cash equivalents amounting to EUR 13.1 million as of September 30, 2024.
What is the expected future performance of TWYMEEG®?
Poxel projects net sales for TWYMEEG® in Japan to reach at least JPY 5 billion, which would trigger significant royalty payments.
What are Poxel's future plans regarding financial resources?
Poxel expects its financial resources to adequately support operating costs and capital expenditures through 2025.
What are the upcoming financial announcements for Poxel?
Poxel plans to release its First Half Results on December 9, 2024, and a Fourth Quarter 2024 update on February 12, 2025.
